Baylor College of Medicine partnership extended to include development of novel combination therapies to treat liver and lung cancers.

Baylor Medical College, Houston, Texas (Baylor) is a leading pioneer in the development of Virus-Specific T Cell technology for the treatment of cancers.  In October 2016, Tessa Therapeutics further cemented its research partnership with Baylor by signing a co-development agreement to develop novel combination therapeutics for liver cancer and lung cancer by combining CAR-T Cell and Virus-Specific T Cell technologies. Tessa Therapeutics has exclusive rights to license all IP generated under the Co-Development Program, which will initially focus on pre-clinical development of at least two therapeutic candidates for both liver, and lung cancer, followed by early stage clinical evaluation.